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Background. The interim results of the Cardiac Arrhythmia Suppression Trial requires physicians to use a higher threshold for employing antiarrhythmic agents in the treatment of benign or potentially lethal ventricular arrhythmias. Many have managed patients by switching to the traditional class I quinidine despite its known proarrhythmic tendency.
Methods and Results. To evaluate the relation between quinidine therapy and mortality in patients with benign or potentially lethal ventricular arrhythmias, we performed a metaanalysis on four randomized double-blind active controlled parallel trials evaluating 1, 909 patients in which quinidine (n =502) was compared to flecainide (n = 141), mexiletine (ni=246), tocainide (n=67), and propafenone (n=53). All four trials had similar patient selection, protocols, and methodology (e.g., placebo lead-in and Holter monitoring) but varying lengths of drug exposure. A total of 12 deaths were reported on quinidine and four deaths on the other drugs: two on mexiletine, one on flecainide, and one on tocainide. The statistical analysis of the mortality rates was based on techniques for combining data across separate strata. Based on maximum likelihood estimation, the combined risk of dying on quinidine was statistically significantly higher compared to the other four drugs with a risk difference of 1.6%. The 95% confidence interval was 0-3.1% (p=0.05). The likelihood ratio test for uniformity of-the risk difference across strata showed the trials to be homogeneous (p=0.88). There was one death recorded for the placebo lead-in period (2 weeks' exposure for 624 patients and 1 week for 385 patients), and seven deaths were reported within 2 weeks on active drug treatment -six on quinidine and one on mexiletine. Furthermore, proarrhythmia was reported in 20 patients on quinidine versus 11 patients on the four other drugs (p=0.09).
Conclusions. These ing; 2) a randomized double-blind parallel group trial design; and 3) explicit reporting of deaths in the trial report. Any comparative trials that did not meet these criteria were classified as appropriate for a quantitative sensitivity analysis or were used for a qualitative review to verify the logical consistency of findings. Searches and review of the articles were conducted independently by both authors. The primary outcome measure was the presence or absence of death as reported in these studies. In addition, the articles were carefully reviewed for the occurrences of the exacerbation or provocation of ventricular arrhythmias (early proarrhythmic response). 5 Various statistical methods were applied to the mortality data extracted from the trials. We had to assume that the data were accurately reported. These methods allowed the data to be combined across studies in a conceptual and statistically meaningful manner rather than simple aggregation of the individually reported results. 8 The parameters used for analysis were the risk difference, relative risk, and the odds ratio.9 Parameter estimates, corresponding 95% confidence intervals, and tests of homogeneity across the various studies are presented. Various statistical methods and parameters (risk difference, relative risk, and odds ratio) are reported because 1) a single approach has not clearly been chosen to be superior,10°11 2) comparing the estimates by different statistical models allows an assessment of the robustness of the findings, including separating potential methodological variations from those associated with the data themselves, and 3) other meta-analyses that are important to understanding the clinical significance of our results used varying methods for reporting their results. The risk difference parameter was selected to receive primary attention because of its direct clinical interpretation; that is, it is the difference in proportions of deaths in patients exposed to quinidine compared to the other class I antiarrhythmic agents. The Mantel-Haenszel x2 statistic was used to test the hypothesis of equal mortality and early proarrhythmic events between quinidine and the comparative agents combined across studies. ' Anderson, 28 noted that data on 6,177 patients randomized to class lb agents and 6,076 patients randomized to placebo resulted in an odds ratio for enhanced mortality due to active therapy of 1.29 (95% confidence interval 1.04 to 1.62, p=0.02). Mexiletine and tocainide are agents with class lb action. Thus, as reported here, quinidine's enhanced risk of mortality is being compared to agents on which there are data that documented an absolute elevation of death compared to placebo (the class Ic drugs) and to agents on which the suspicion of increased risk is moderate to high (the class lb drugs).
Our study also shows a trend toward an increased rate of proarrhythmia on quinidine compared to a combined rate on the other four class I agents (p=0.09). These data give an empiric basis for the general impression of cardiologists who subsequently ranked quinidine as the most proarrhythmic drug in their experience when given to patients with benign or potentially lethal ventricular arrhythmias. 3 The results of the current study are further strengthened when considered co-jointly with that of an analysis performed by Coplen et a129 in 800 patients in which quinidine was compared to placebo in the treatment of atrial fibrillation. In their meta-analysis, 12 out of 413 (2.9%) patients exposed to quinidine died versus three deaths out of 387 (0.8%) patients given placebo, in a 3-12-month follow-up. These investigators reported a Mantel-Haenszel odds ratio of 3.51, with a 95% confidence interval of 0.99 to 12.45 (p=0.05). The MantelHaenszel-Peto method yielded an odds ratio of 2.98 with a 95% confidence interval of 1.1 to 8.3 (p<0.05). These results are highly suggestive of increased mortality on quinidine. In our analysis, the odds of dying on quinidine was also about three times that compared to the odds of dying on an active comparative agent; the respective estimates being 3.08 and 2.78 (Table 3) .
Examining The potential interaction of digoxin and quinidine may contribute to late proarrhythmia. The trials included in this report were conducted when this interaction was well known, and the protocols clearly recommended a reduction in digoxin dosage. However, in the quinidine versus mexiletine trial there were two deaths among the 185 patients who were on quinidine without digoxin use versus five deaths in the 60 patients in the group on quinidine plus concomitant digoxin. 18 Overall, 60 of 245 (24.5%) patients randomized to quinidine compared to 56 of 246 (22.8%) patients assigned to mexiletine were being treated with digoxin. Also, in the flecainide versus quinidine trial, there was one death in the 103 patients on quinidine without concomitant digoxin compared to two deaths among the 36 patients who were on both quinidine and digoxin.17 Thus, the increased deaths on quinidine may be related to concomitant digoxin use or to an enhanced mortality risk when quinidine is used in patients treated with digoxin presumably due to the coexistence of poor left ventricular function.
The meta-analysis provided in this report satisfies the characteristics required for valid use of this technique. The four parallel trials had comparable study designs and data presentation as well as enrolling similar patient populations. In addition, all studies were conducted within a specific drug class (class I). Although 53% of the data were contributed by the 12-week quinidine-mexiletine study, the results are consistent over the other three shorter-term trials. 18 Moreover, the combining of all the data is logical due to the similar class I status of the comparative agents and the statistical finding of homogeneity across the separate trials.
The effect of suppression of benign or potentially lethal ventricular arrhythmias has been previously reported in 446 patients in 17 trials by a metaanalysis of Salerno et al. 34 The percentage of patients responding to quinidine was 53% with a range of 43 to 63%. The efficacy rate demonstrated in the four trials reported here ranged between 32 to 83% of patients responding. In the meta-analysis of Salerno et al,34 the average percent of responders for 100% suppression of nonsustained ventricular tachycardia was 57% with a range of 21 to 92% in 158 treated patients in nine studies. In the four studies reported here, the response rates ranged between 43 and 80%.
Our analysis of quinidine's effect is limited to the short-to-medium-term drug exposure from 2 to 12 weeks, which is typical for ventricular arrhythmia treatment studies. The deaths reported in the original clinical trials were not considered for their potential as a late occurring proarrhythmic event and often were ascribed to natural occurrences. This retrospective analysis, in view of the mortality results of the Cardiac Arrhythmia Suppression Trial, necessitated that the deaths be more closely inspected and presented (Table 5) . 4, [17] [18] [19] [20] The results of this meta-analysis do not address the concern of the use of antiarrhythmic agents in the treatment of life-threatening or sustained ventricular tachyarrhythmias, but similar caution in the use of quinidine over the long term should be considered. It is also clear that no quinidine versus placebo comparative trials, in any form of ventricular arrhythmias, are likely to occur in the future, although this would be the only definitive way of defining the true rate of late proarrhythmic mortality from quinidine therapy.
Clearly the results of the Cardiac Arrhythmia Suppression Trial cautioned against the prophylactic use of antiarrhythmic therapy for sudden cardiac death prevention in postmyocardial infarction patients with asymptomatic potentially lethal ventricular arrhythmias. 45 Currently, /3-blockers are the only "antiarrhythmic" agents that have been shown to demonstrate long-term safety in this regard. The only current class I agent with adequate long-term safety data appears to be moricizine because it continues to be studied in Phase II of the Cardiac Arrhythmia Suppression Trial. 5 The implications of our findings complement and support the growing literature on the enhanced risk of mortality from quinidine and provides further impetus to the cautious use of any antiarrhythmic agents in which the benefit has not been shown to outweigh the potential harm.
